New screening technology works to better predict drug’s shelf life and stability

pharmaceuticals
Credit: Pixabay/CC0 Public Domain

Biopharmaceuticals are a fast-growing sector of the pharmaceutical market, but these protein-based drugs can take many years to bring to market and cost more than $2 billion to develop. A large portion of that time and money is spent attempting to predict which drug from a vast library of candidates is the most stable and will have the longest shelf life. TemperSure, a new drug screening technology from Penn State startup GradienT°, aims to reduce both the time and financial costs in biological drug development by increasing certainty in drug shelf life and expiration dates.

“The challenge for drug developers is that they need to ‘place their bet’ on which drug candidate to further develop, and the costs associated with getting it wrong are significant,” said Dustin Ritter, Penn State technology licensing officer and GradienT°’s industry mentor. “TemperSure’s value lies in its ability to quickly predict

Read More